JP2015529633A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529633A5
JP2015529633A5 JP2015517672A JP2015517672A JP2015529633A5 JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5 JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015517672 A JP2015517672 A JP 2015517672A JP 2015529633 A5 JP2015529633 A5 JP 2015529633A5
Authority
JP
Japan
Prior art keywords
bag3
biological sample
antibody
urine
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015517672A
Other languages
English (en)
Other versions
JP6654432B2 (ja
JP2015529633A (ja
Filing date
Publication date
Priority claimed from EP12172531.1A external-priority patent/EP2676966A1/en
Application filed filed Critical
Publication of JP2015529633A publication Critical patent/JP2015529633A/ja
Publication of JP2015529633A5 publication Critical patent/JP2015529633A5/ja
Application granted granted Critical
Publication of JP6654432B2 publication Critical patent/JP6654432B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 生物学的試料において、抗BAG3抗体または抗BAG3抗体が可溶性BAG3に結合して形成された免疫複合体の存在を検出することによって特徴付けられた病理学的状態の診断の方法であって、
    a.血清、血漿、尿、または唾液からなる生物学的試料を得るステップと、
    b.生物学的試料における抗BAG3またはBAG3関連抗体の存在を決定するステップと、
    を含み、
    前記病理学的状態は、心臓疾患、癌、ならびに、炎症および炎症性関連疾患であって、皮膚、神経、骨、血管、および結合組織の炎症および炎症性関連疾患から選択され、および、
    前記診断は、インビトロまたはエキソビボである、
    ことを特徴とする方法。
  2. c.生物学的試料から得た値を、基準値または健康な提供者から得た値と比較するステップ、
    をさらに含むことを特徴とする請求項1に記載の方法。
  3. 前記決定ステップbは、ELISA検査により実施されることを特徴とする請求項1に記載の方法。
  4. 前記血清、血漿、尿、または唾液は、哺乳類、好ましくはヒト由来であることを特徴とする請求項1から3のいずれか一項に記載の方法。
  5. 前記心臓疾患は、狭心症、梗塞前狭心症、心筋梗塞、心不全、急性冠疾患、虚血、急性心不全、慢性心不全、または医原性心疾患から選択されることを特徴とする請求項1に記載の方法。
  6. 前記癌は、膵癌、膀胱癌、および前立腺癌から選択されることを特徴とする請求項1に記載の方法。
  7. ELISAキットの使用であって、
    前記ELISAキットは、BAG3組換えタンパク質または可溶性BAG3を捕捉するBAG3特異的マウスモノクローナル抗体AC−1、AC−2 AC−3、AC−4、AC−5、AC−rb1a、AC−rb1b、AC−rb2a、AC−rb2b、AC−rb3a、AC−rb3b、AC−rb4a、およびAC−rb4b、ならびに、ヒト免疫グロブリンを認識することができる抗体を含み、
    前記キットは、生物学的試料において可溶性BAG3と結合して免疫複合体を形成する抗−BAG3抗体または抗−BAG3抗体の検出をするために用いられるものであることを特徴とするELISAキットの使用。
  8. 前記生物学的試料は、血清、血漿、尿、または唾液試料であることを特徴とする請求項7に記載の使用。
  9. 前記血清、血漿、尿、または唾液試料は、哺乳類、好ましくはヒト由来であることを特徴とする請求項8に記載の使用。
JP2015517672A 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3 Expired - Fee Related JP6654432B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12172531.1 2012-06-19
EP12172531.1A EP2676966A1 (en) 2012-06-19 2012-06-19 BAG3 as biochemical serum and tissue marker
PCT/EP2013/061976 WO2013189778A1 (en) 2012-06-19 2013-06-11 Bag3 as biochemical serum and tissue marker

Publications (3)

Publication Number Publication Date
JP2015529633A JP2015529633A (ja) 2015-10-08
JP2015529633A5 true JP2015529633A5 (ja) 2016-07-28
JP6654432B2 JP6654432B2 (ja) 2020-02-26

Family

ID=48607259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517669A Pending JP2015521475A (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3
JP2015517672A Expired - Fee Related JP6654432B2 (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015517669A Pending JP2015521475A (ja) 2012-06-19 2013-06-11 生化学的血清マーカーおよび組織マーカーとしてのbag3

Country Status (12)

Country Link
US (2) US10359433B2 (ja)
EP (3) EP2676966A1 (ja)
JP (2) JP2015521475A (ja)
KR (2) KR20150036102A (ja)
CN (2) CN104619861A (ja)
AU (2) AU2013279604B2 (ja)
BR (2) BR112014031958A2 (ja)
CA (2) CA2876872A1 (ja)
ES (1) ES2795981T3 (ja)
IN (2) IN2014DN10562A (ja)
PL (1) PL2861618T3 (ja)
WO (2) WO2013189775A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒
CN105769900A (zh) * 2016-03-22 2016-07-20 山西大学 Bag3基因在制备抗膀胱癌药物中的应用
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US11940450B2 (en) 2021-03-16 2024-03-26 University Of Connecticut Biomarker panel for non-invasive diagnosis of congenital renal dysfunction
CN113862361B (zh) * 2021-10-25 2023-08-15 中山大学孙逸仙纪念医院 一种诊断和治疗膀胱癌的分子标志物hsf1及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
CA2379264A1 (en) * 1999-07-09 2001-01-18 The Burnham Institute A method for determining the prognosis of cancer patients by measuring levels of bag expression
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP1323733A1 (en) * 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
WO2011044927A1 (en) * 2009-10-12 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the diagnosis or prognosis of an advanced heart failure
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
GB201017520D0 (en) * 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers

Similar Documents

Publication Publication Date Title
JP2015529633A5 (ja)
Meijers et al. Heart failure stimulates tumor growth by circulating factors
Wu Release of cardiac troponin from healthy and damaged myocardium
Quilici et al. Circulating endothelial cell count as a diagnostic marker for non–ST-elevation acute coronary syndromes
Berezin et al. Pattern of circulating microparticles in chronic heart failure patients with metabolic syndrome: Relevance to neurohumoral and inflammatory activation
Shere et al. Circulating blood biomarkers in essential hypertension: a literature review
Cardinale et al. Role of biomarkers in cardioncology
EA201070738A1 (ru) Композиции и способы детекции tiab
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
WO2013068374A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
WO2011161062A3 (en) Lipidomic biomarkers for identification of high-risk coronary artery disease patients
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2014144959A5 (ja)
Gruden et al. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma
CA2509063A1 (en) Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
Iversen et al. Pregnancy associated plasma protein-A (PAPP-A) is not a marker of the vulnerable atherosclerotic plaque
FI3356827T3 (fi) GDF-15 diagnostisena markkerina immuunivasteen vapauttajilla annetun hoidon hoitovasteen ennustamiseksi
Chen et al. Association of serum angiopoietin‑1, angiopoietin‑2 and angiopoietin‑2 to angiopoietin‑1 ratio with heart failure in patients with acute myocardial infarction
Nyström et al. Type IV collagen as a tumour marker for colorectal liver metastases
Villacorta et al. Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure
Vasatova et al. Current applications of cardiac troponin T for the diagnosis of myocardial damage
WO2014167969A1 (ja) 大腸がんの検出方法
Schmid et al. ST2 predicts survival in patients undergoing transcatheter aortic valve implantation
RU2670052C1 (ru) Антигенный полипептид для выявления в плазме крови иммунного маркера - аутоантитела к vegfr1 и его применение